Verve Therapeutics, Inc. Lessee, Operating Lease, Liability, to be Paid, Year Two in USD from Q3 2021 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
Summary
Verve Therapeutics, Inc. quarterly Lessee, Operating Lease, Liability, to be Paid, Year Two history and growth rate from Q3 2021 to Q1 2025.
  • Verve Therapeutics, Inc. Lessee, Operating Lease, Liability, to be Paid, Year Two for the quarter ending March 31, 2025 was $11.2M, a 0.01% increase year-over-year.
Lessee, Operating Lease, Liability, to be Paid, Year Two, Quarterly (USD)
Lessee, Operating Lease, Liability, to be Paid, Year Two, YoY Quarterly Growth (%)

Verve Therapeutics, Inc. Quarterly Lessee, Operating Lease, Liability, to be Paid, Year Two (USD)

Period Value YoY Chg Change % Date Report Filed
Q1 2025 $11.2M +$1K +0.01% Mar 31, 2025 10-Q 2025-05-14
Q4 2024 $11.2M +$342K +3.15% Dec 31, 2024 10-K 2025-02-27
Q3 2024 $11.2M +$342K +3.15% Sep 30, 2024 10-Q 2024-11-05
Q2 2024 $11.2M +$342K +3.15% Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $11.2M +$647K +6.13% Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $10.9M +$305K +2.89% Dec 31, 2023 10-K 2024-02-27
Q3 2023 $10.9M -$315K -2.82% Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $10.9M +$886K +8.88% Jun 30, 2023 10-Q 2023-08-10
Q1 2023 $10.6M +$585K +5.86% Mar 31, 2023 10-Q 2023-05-15
Q4 2022 $10.6M +$605K +6.08% Dec 31, 2022 10-K 2023-03-02
Q3 2022 $11.2M +$1.52M +15.7% Sep 30, 2022 10-Q 2022-11-07
Q2 2022 $9.98M Jun 30, 2022 10-Q 2022-08-09
Q1 2022 $9.98M Mar 31, 2022 10-Q 2022-05-10
Q4 2021 $9.96M Dec 31, 2021 10-K 2022-03-14
Q3 2021 $9.67M Sep 30, 2021 10-Q 2021-11-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.